Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Mycobacterium tuberculosis antigen + physiological saline
- Development stage
- Preclinical
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a combination product consisting of recombinant antigens derived from Mycobacterium tuberculosis and physiological saline as the diluent or vehicle. Recombinant M. tuberculosis antigens are engineered proteins, such as ESAT-6, CFP-10, PE35, nDnaK, 85-C protein, or Rv0942 protein, produced in host systems like E. coli for use in vaccine development or immunological research[1][2][3][4][5]. These antigens are designed to stimulate an immune response against M. tuberculosis by presenting key epitopes to the immune system and inducing Th1-type cellular immunity (e.g., IFN-γ production), which is critical for protection against TB[1][4]. Physiological saline serves as an isotonic carrier solution for administration.
- Other names
- recombinant Mycobacterium tuberculosis antigen + physiological saline
02
Targets
BCR (Immunoglobulin G B Cell Receptor)Hla (Staphylococcus aureus alpha toxin)T cell receptor recognizing Mycobacterium tuberculosis peptide-MHC complexes
Beyond the preview
Go deeper on recombinant Mycobacterium tuberculosis antigen + physiological saline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Mycobacterium tuberculosis antigen + physiological saline.